QEL-001 is under clinical development by Quell Therapeutics and currently in Phase II for Liver Transplant Rejection. According to GlobalData, Phase II drugs for Liver Transplant Rejection have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how QEL-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

QEL-001 overview

QEL-001 is under development for the treatment of liver transplant rejection. It is administered through intravenous route in the form of suspension. The therapeutic candidate comprises of autologous T regulatory cells transduced with a lentiviral vector containing a CAR directed against HLA-A2.

Quell Therapeutics overview

Quell Therapeutics (Quell) is a biopharmaceutical company that develops engineered T-regulatory (Treg) cell therapies for the treatment of autoimmune and inflammatory diseases. The company’s pipeline products include QEL-001 and QEL-002. Its QEL-001, candidate treats liver transplantation. Quell utilizes proprietary technology to enable the targeting of tregs in an antigen (Ag)-specific manner within the body. The company’s funding partners include Tekla Capital Management LLC, Fidelity Management and Research Company LLC, Jeito, Monashee Investment Management LLC and British Patient Capital, among others. Quell is headquartered in London, England, the UK.

For a complete picture of QEL-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.